Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents

Journal of Nippon Medical School

Volumn 76, Issue 1, 2009, Pages 4-8

  Gemma, Akihiko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Anticancer agents; Interstitial lung disease; Molecular target

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB;

CLINICAL TRIAL; COMPREHENSION; EVIDENCE BASED PRACTICE; HUMAN; IMAGING; INTERSTITIAL PNEUMONIA; JAPAN; LUNG EDEMA; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; PATHOLOGY; POSTMARKETING SURVEILLANCE; REVIEW; RISK; RISK FACTOR;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG DISEASES, INTERSTITIAL;

EID: 63149179258     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.76.4     Document Type: Review

References (10)

1. Final report of the expert committee on acute lung diseases/interstitial pneumonia due to gefitinib (Irresa® Tablets 250), AstraZeneca, March 2003.
2. "Results and discussion of the prospective survey on the use of Irresa® Tablets 250 (Special survey)", AstraZeneca, August 2004.
3. Kudoh S, Kato H, Nishiwaki Y, et al.: Japan Thoracic Radiology Group Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008; 177: 1348-1357.
4. Gemma A: Special article "The science of adverse reaction": II Outline of adverse reaction; 14) anticancer agents; d) interstitial pneumonia [in Japanese]. Jap J Clin Med (Nihon Rinsyo) 2007; 65 (Supple 8): 299-303.
5. Gemma A: Lung diseases due to anti-malignant tumor agents [in Japanese]. Clin Oncology (Shuyo Naika) 2007; 1: 177-183.
6. Instruction for appropriate use of Tarceba® Tablets. Chugai Pharmaceutical.
7. Miyakoshi S, Kami M, Yuji K, et al.: Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006; 107: 3492-3494.
8. Gotoh A, Ohyashiki K, Oshimi K, et al.: Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology. Int J Hematol 2006; 84: 406-412.
9. Instruction for appropriate use of Velcade®. Janssen Pharmaceutical, 2006.
10. Interim report on clinical studies of Velcade® Injection 3 mg. Janssen Pharmaceutical, 2007.